

**Indiana Hoosier Healthwise  
PDL Changes  
August 2008 DUR Board Presentation**

**Additions to PDL with NO Clinical Edits**

Cetirizine OTC products  
Ocella  
Risperidone

**Additions to PDL with Clinical Edits**

NA

**Removal of Clinical Edits from Existing PDL products**

NA

**Addition of Clinical Edits to Existing PDL products**

<b>Product</b>	<b>Edit</b>
ASTELIN	PA Criteria- inability to achieve efficacy or experiences side effects with non-sedating oral antihistamines (cetirizine, loratadine) or intranasal corticosteroids (flunisolide, fluticasone)
AUGMENTIN XR, AUGMENTIN BRAND CHEWABLES	PA Criteria- Patient has a diagnosis of Community Acquired Pneumonia OR the inability to achieve efficacy or experiences side effects with generically available amoxil and/or augmentin products
DIFFERIN	Currently the PA is for members under 12 or over 35. Expand PA Criteria to include all age members with a diagnosis of acne vulgaris that are unable to achieve efficacy or experience side effects with generic TRETINOIN products
PLAVIX	QL of 1 tablet per day; PA Criteria- inability to achieve efficacy or has an allergy to or experiences side effects with ASPIRIN
PULMICORT RESPULES, FLEXHALER	RESPULES: Member is less than 6 years of age; OR Member is 6 years of age or older and is unable to use an oral inhaler FLEXHALER: Member is unable to achieve efficacy with QVAR (beclomethasone dipropionate) oral inhaler; OR Member has been receiving Pulmicort Flexhaler for 90 days or more in the previous 6 months
SINGULAIR	PA criteria to align with treatment guidelines for members over the age of 5: For allergic rhinitis - inability to achieve efficacy or experiences side effects with non-sedating oral antihistamines (cetirizine, loratadine) or intranasal corticosteroids (flunisolide, fluticasone); For asthma - inability to achieve efficacy or experiences side effects with inhaled corticosteroid therapy

VIGAMOX	PA Criteria to include members with a diagnosis of bacterial conjunctivitis that are unable to achieve efficacy or experience side effects with generic preferred ophthalmic antibiotics including ciprofloxacin or ofloxacin
---------	---

### Change to Non-Preferred

Product	Rationale	Alternative
AEROBID, AEROBID M, ASMANEX, AZMACORT	Comparable safety and efficacy to other preferred corticosteroid inhalers	PDL alternatives include QVAR, FLOVENT, PULMICORT
APIDRA, LEVEMIR	Comparable safety and efficacy to other preferred insulin products	PDL alternatives include LANTUS, HUMULIN & NOVOLIN brands of insulin
CILOXAN	Comparable safety and efficacy to other preferred ophthalmic antibiotic products	PDL alternatives include generic ophthalmic agents CIPROFLOXACIN and OFLOXACIN
DUAC	Comparable safety and efficacy to other preferred acne products	PDL alternatives include generic agents BENZOYL PEROXIDE/CLINDAMYCIN and BENZOYL PEROXIDE/ERYTHROMYCIN
GLYSET	Comparable safety and efficacy to generic preferred alpha-glucosidase inhibitor	PDL alternative includes generic ACARBOSE
LOVAZA/OMACOR	Dietary supplement for risk of CAD. AHA recommends consumption of fish; however, it does not find justification for fish oil capsule supplementation (online Facts and Comparisons).	PDL alternatives include generic NIACIN, LOVASTATIN, SIMVASTATIN
TOBRADEX	Comparable safety and efficacy to other preferred products	PDL alternatives include generic ophthalmic agents: NEOMYCIN/BACITRACIN/POLY/HC NEOMYCIN/POLYMYXIN/DEXAMETH NEOMYCIN/POLYMYXIN/HC
TRICOR	Comparable safety and efficacy to other preferred products	PDL alternatives include generic FENOFIBRATE